Exelixis(US:EXEL) ZACKS·2026-02-10 23:25分组1 - Exelixis reported quarterly earnings of $0.94 per share, exceeding the Zacks Consensus Estimate of $0.77 per share, and showing an increase from $0.55 per share a year ago, resulting in an earnings surprise of +22.25% [1] - The company achieved revenues of $598.66 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.39% and increasing from $566.76 million year-over-year [2] - Exelixis has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.76 on revenues of $618.11 million, while for the current fiscal year, the estimate is $3.39 on revenues of $2.57 billion [7] - The Medical - Biomedical and Genetics industry, to which Exelixis belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]